News | Peripheral Artery Disease (PAD) | January 26, 2021

Pedra Tissue Perfusion System Receives FDA Breakthrough Device Designation

Novel perfusion monitor allows real-time, periprocedural monitoring of tissue perfusion in patients with critical limb threatening ischemia

The Pedra Blood Perfusion Index tracks real-time changes in foot tissue perfusion attendant with balloon inflation and deflation during an angioplasty procedure.

The Pedra Blood Perfusion Index tracks real-time changes in foot tissue perfusion attendant with balloon inflation and deflation during an angioplasty procedure.


January 26, 2021 — Pedra Technology, a privately held company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for the periprocedural use of its Pedra Xauron Perfusion System in the treatment of critical limb threatening ischemia (CLTI).

CLTI is a severe form of peripheral artery disease (PAD) that is defined as ischemic rest pain, tissue loss, or gangrene (tissue death) that develops as a result of chronically poor blood flow to the lower limbs. If left untreated, CLTI can lead to limb amputation or death.  The 1-year mortality rate of CLTI patients without amputation is 30.3% and with amputation is 40.4%.  At 5-years post-CLTI diagnosis, the mortality rate exceeds 50%, which is worse than most cancers.

The Breakthrough Devices Program at the FDA aims to provide patients and providers with timely access to medical devices that provide for more effective treatment and diagnosis of severe diseases, including a prioritized review of market approval regulatory submissions.

“This Breakthrough Device Designation recognizes the compelling need for real-time tissue perfusion monitoring during lower limb revascularization procedures for the treatment of CLTI.  To my knowledge, this is the first perfusion monitor for CLTI that has received this designation,” said Kareen Looi, CEO of Pedra Technology. “An improvement in microvascular perfusion at the tissue level is necessary for elimination of rest pain, healing of chronic wounds and for limb salvage.  We look forward to developing this important new technology and working closely with the FDA to develop the appropriate clinical program for market approval.”  

Paul Hayes, M.D., vascular surgeon and CMO of Pedra Technology, commented, “With the Xauron device, physicians can at last see real-time perfusion changes during an interventional procedure in the angiographic suite. I’m excited about building on our early clinical data and demonstrating that Xauron will save patient lives and limbs.”

The Pedra XauronPerfusion System is not currently approved for sale in the U.S.

For more information: Pedratech.com

 


Related Content

News | Peripheral Artery Disease (PAD)

June 6, 2025 – A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 ...

Home June 06, 2025
Home
News | Peripheral Artery Disease (PAD)

Feb. 3, 2025 — Today, Peripheral Artery Disease (PAD) affects 10 million Americans and is the most common cause of limb ...

Home February 04, 2025
Home
News | Peripheral Artery Disease (PAD)

Jan. 13, 2025 – R3 Vascular Inc., a medical device company dedicated to treating peripheral arterial disease (PAD) ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

A new study reports persistent disparities in outcomes for people with peripheral artery disease (PAD) and its more ...

Home January 13, 2025
Home
News | Peripheral Artery Disease (PAD)

Dec. 13, 2024 – Sensome has announced positive results from two studies of its Clotild Smart Guidewire System ...

Home December 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 18, 2024 — In November, Esperion presented an analysis from the CLEAR Outcomes study focused on patients with ...

Home December 03, 2024
Home
News | Peripheral Artery Disease (PAD)

Nov. 4, 2024 — Royal Philips recently announced enrollment of the first patient in the U.S. THOR IDE clinical trial ...

Home November 08, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech, has announced the full U.S. launch of the ...

Home September 16, 2024
Home
News | Peripheral Artery Disease (PAD)

Sept. 1, 2024 — September is Peripheral Artery Disease (PAD) Awareness Month, a time to educate and empower people to ...

Home September 04, 2024
Home
News | Peripheral Artery Disease (PAD)

May 16, 2024 — Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care ...

Home May 16, 2024
Home
Subscribe Now